Strategic Partnerships CDI has demonstrated collaboration with clinical trial platforms (CliniOps) to support GI research. This presents sales opportunities to offer CDI-based non-invasive breath tests as part of end-to-end trial protocols, appealing to CROs and research networks seeking reliable, patient-friendly diagnostics.

Non-Invasive Growth With a focus on at-home breath tests for SIBO, IMO, and malabsorption, CDI offers scalable, low-friction diagnostic solutions. Market potential exists to monetize through healthcare providers expanding GI testing portfolios, telehealth partnerships, and direct-to-consumer testing channels.

Regulatory & Quality CDI operates a CLIA-certified laboratory and maintains FDA-registered, ISO 13485-certified manufacturing. This strong compliance posture can be leveraged to win contracts with hospitals, clinics, and device distributors requiring validated, high-quality diagnostics.

Tech & Reach A diversified tech stack including cloud, marketing automation, and digital media indicates active patient and clinician engagement. Sales opportunities exist to deploy integrated marketing partnerships, data-driven outreach, and digital onboarding for new customers.

Financial Reach With annual revenue in the low-to-mid millions and a lean team, CDI is positioned for rapid expansion through strategic deals, white-labeling, or joint ventures with larger labs and diagnostics players to scale distribution and capabilities.